Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-32 inhibitor (Arch Biopartners)
- Development stage
- Preclinical
- Lead developer
- 1502440
01
Overview
Arch Biopartners is developing a therapeutic platform targeting interleukin-32 (IL-32) for the treatment of diabetic kidney disease (DKD) and chronic kidney disease (CKD). IL-32 is a non-classical cytokine involved in regulating inflammation and immune responses, which has been implicated in the pathogenesis of diabetic CKD. The program is a result of a collaboration between the National Research Council of Canada (NRC), Lipdro, and Arch Biopartners. Currently in the preclinical stage, the company is working toward selecting a lead candidate and filing an Investigational New Drug (IND) application with the FDA.
- Other names
- CKD PlatformIL-32 programIL32 programIL 32 program
02
Targets
IL32 (IL-32)
Beyond the preview
Go deeper on IL-32 inhibitor (Arch Biopartners).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-32 inhibitor (Arch Biopartners).